RMD
$233.50
ResMed Inc.
Intraday
Recent News
ResMed (RMD) Upgraded to Buy: Here's What You Should Know
ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Resmed Stock the Right Pick for Your Portfolio Now?
RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.
After Plunging 8.7% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)
The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is It Time To Reconsider ResMed (RMD) After The Recent Share Price Pullback
If you are wondering whether ResMed's current share price still reflects good value or if most of the upside is already priced in, you are in the right place. ResMed shares last closed at US$230.84, with returns of 3.9% over 1 year, 14.7% over 3 years, 29.9% over 5 years, and more recent moves of an 8.7% decline over 7 days and an 11.1% decline over 30 days that may be changing how the market views its risk and return trade off. Recent coverage of ResMed has focused on the company as a major...
Is ResMed Stock Underperforming the Nasdaq?
ResMed has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.